Positions

Selected Publications

Academic Article

Year Title Altmetric
Aberrant Glycosylation of the IgA1 Molecule in IgA NephropathySeminars in Nephrology.  38.
Aberrant O-glycosylation and anti-glycan antibodies in an autoimmune disease IgA nephropathy and breast adenocarcinomaCellular and Molecular Life Sciences.  70:829-839.
Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneityJournal of Clinical Investigation.  119:1668-1677.
Advances in urinary proteome analysis and biomarker discoveryJournal of the American Society of Nephrology.  18:1057-1071.
An update on the treatment of IgA nephropathy
Analysis of O-glycan heterogeneity in IgA1 myeloma proteins by Fourier transform ion cyclotron resonance mass spectrometry: Implications for IgA nephropathy
Antibody-mediated protection and the mucosal immune system of the genital tract: Relevance to vaccine designJournal of Reproductive Immunology.  85:81-85.
Application of proteomic analysis to renal disease in the clinic
Autoantibodies Specific for Galactose-Deficient IgA1 in IgA Vasculitis With NephritisKidney International Reports.  4:1717-1724.
Autoantibodies targeting galactose-deficient IgA1 associate with progression of IgA nephropathyJournal of the American Society of Nephrology.  23:1579-1587.
Biochemical structural analysis of the lantibiotic mutacin IIJournal of Biological Chemistry.  275:15845-15850.
Biosynthesis of avermectins and lipids in Streptomyces avermitilis
CE-MS analysis of the human urinary proteome for biomarker discovery and disease diagnostics
Characterization of PepB, a group B streptococcal oligopeptidaseInfection and Immunity.  64:3401-3406.
Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodiesJournal of Clinical Investigation.  104:73-81.
Clinical Characteristics and Treatment Patterns of Children and Adults With IgA Nephropathy or IgA Vasculitis: Findings From the CureGN StudyKidney International Reports.  3:1373-1384.
Comparison of methods for profiling O-glycosylation: Human proteome organisation human disease glycomics/proteome initiative multi-institutional study of IgA1Molecular and Cellular Proteomics.  9:719-727.
Comprehensive human urine standards for comparability and standardization in clinical proteome analysis
Correction: Galactose-deficient IgA1 and the corresponding IgG autoantibodies predict IgA nephropathy progression (PLoS One (2019) 14:2 (e0212254) DOI: 10.1371/journal.pone.0212254)
CureGN Study Rationale, Design, and Methods: Establishing a Large Prospective Observational Study of Glomerular DiseaseAmerican Journal of Kidney Diseases.  73:218.
Current understanding of the role of complement in IgA nephropathyJournal of the American Society of Nephrology.  26:1503-1512.
Detection of modified amino acids in lantibiotic peptide mutacin II by chemical derivatization and electrospray ionization-mass spectroscopic analysisAnalytical Biochemistry.  236:358-360.
Determination of severity of murine IgA nephropathy by glomerular complement activation by aberrantly glycosylated IgA and immune complexes
Diacylglycerol kinase is involved in regulation of expression of the lantibiotic mutacin II of Streptococcus mutansJournal of Bacteriology.  180:167-170.
Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens
Electrophoretic methods for analysis of urinary polypeptides in lgA-associated renal diseasesELECTROPHORESIS.  28:4469-4483.
Expression and protein engineering of the lantibiotic mutacin II
Expression of the recombinant human immunoglobulin J chain in Escherichia coliMolecular Immunology.  37:133-140.
Familial IgA nephropathy in southeastern Kentucky
GWAS for serum galactose-deficient IgA1 implicates critical genes of the O-glycosylation pathwayPLoS Genetics
Galactose-deficient IgA1 in African Americans with IgA nephropathy: Serum levels and heritabilityClinical Journal of the American Society of Nephrology.  5:2069-2074.
Genetic and biochemical analysis of mutacin 1140, a lantibiotic from Streptococcus mutansInfection and Immunity.  66:2743-2749.
Glomerular immunodeposits of patients with IgA nephropathy are enriched for IgG autoantibodies specific for galactose-deficient IgA1Journal of the American Society of Nephrology.  30:2017-2026.
HIV-1 envelope glycan moieties modulate HIV-1 transmissionJournal of Virology.  88:14258.
High resolution proteome/peptidome analysis of body fluids by capillary electrophoresis coupled with MSProteomics.  6:5615-5627.
High-resolution proteome/peptidome analysis of peptides and low-molecular-weight proteins in urine
IgA nephropathy and henoch-schoenlein purpura nephritis: Aberrant glycosylation of IgA1, formation of IgA1-containing immune complexes, and activation of mesangial cellsContributions to Nephrology.  157:134-138.
IgA nephropathy enigmaClinical Immunology.  172:72-77.
IgA nephropathy pathogenetic importance of immunoglobulin a glycosylation and clinical presentation
IgA nephropathy: A clinical overviewContributions to Nephrology.  157:19-26.
IgA nephropathy: An update
IgA-containing immune complexes in the urine of IgA nephropathy patientsNephrology Dialysis Transplantation.  21:2478-2484.
IgA1-containing immune complexes in IgA nephropathy differentially affect proliferation of mesangial cellsKidney International.  67:504-513.
Increased levels of galactose-deficient IgG in sera of HIV-1-infected individualsAIDS.  19:381-389.
Involvement of envelope-glycoprotein glycans in HIV-1 biology and infectionArchivum Immunologiae et Therapiae Experimentalis.  58:191-208.
Isolation and biochemical characterization of a novel lantibiotic mutacin from Streptococcus mutansJournal of Bacteriology.  4316-4320.
Microbially-produced peptides having potential application to the prevention of dental cariesInternational Journal of Antimicrobial Agents.  9:95.
Mutacin II, a bactericidal lantibiotic from Streptococcus mutansAntimicrobial Agents and Chemotherapy.  39:2656-2660.
Nitrogen regulation of fatty acids and avermectins biosynthesis in Streptomyces avermitilis
Oxidative stress and galactose-deficient IgA1 as markers of progression in IgA nephropathyClinical Journal of the American Society of Nephrology.  6:1903-1911.
Production of avermectin A2a and monoglycosides A2a and B2a by a strain of Streptomyces avermitilisFolia Microbiologica.  38:367.
Prognostic value of serum biomarkers of autoimmunity for recurrence of IGA nephropathy after kidney transplantationJournal of the American Society of Nephrology.  28:1943-1950.
Programmed cell death [3]Science.  274:20-21.
Reactivities of N-acetylgalactosamine-specific lectins with human IgA1 proteinsMolecular Immunology.  44:2598-2604.
Recommendations for biomarker identification and qualification in clinical proteomicsScience Translational Medicine.  2.
Reevaluation of the mucosa-bone marrow Axis in IgA nephropathy with animal models
Serum galactose-deficient IgA1 level is not associated with proteinuria in children with IgA nephropathyInternational Journal of Nephrology.  2012.
Serum levels of galactose-deficient immunoglobulin (Ig) A1 and related immune complex are associated with disease activity of IgA nephropathyClinical and Experimental Nephrology.  18:770-777.
Somatic mutations modulate autoantibodies against galactose-deficient IgA1 in IgA nephropathyJournal of the American Society of Nephrology.  27:3278-3284.
Sources of urinary proteins and their analysis by urinary proteomics for the detection of biomarkers of disease
Structure-activity study of the lantibiotic mutacin II from Streptococcus mutans T8 by a gene replacement strategyApplied and Environmental Microbiology.  64:2335-2340.
Sugars and alcohol: IgA-associated renal diseases in alcoholic cirrhosisKidney International.  80:1252-1254.
The IgA1 immune complex-mediated activation of the MAPK/ERK kinase pathway in mesangial cells is associated with glomerular damage in IgA nephropathyKidney International.  82:1284-1296.
The combined role of galactose-deficient IgA1 and streptococcal IgA-binding M protein in inducing IL-6 and C3 secretion from human mesangial cells: Implications for IgA nephropathyJournal of Immunology.  193:317-326.
The emerging role of complement proteins as a target for therapy of IgA nephropathyFrontiers in Immunology.  10.
The level of galactose-deficient IgA1 in the sera of patients with IgA nephropathy is associated with disease progressionKidney International.  82:790-796.
The serum very-low-density lipoprotein serves as a restriction factor against hepatitis C virus infectionJournal of Virology.  89:6782-6791.
The specific genes for lantibiotic mutacin II biosynthesis in Streptococcus mutans T8 are clustered and can be transferred en blocApplied and Environmental Microbiology.  65:1356-1360.
Toward Noninvasive Diagnosis of IgA Nephropathy: A Pilot Urinary Metabolomic and Proteomic StudyDisease Markers.  2016.
Treatment of IgA nephropathy
Upregulated proteoglycan-related signaling pathways in fluid flow shear stress-treated podocytes
What insights can proteomics give us into IgA nephropathy (Berger’s disease)?Expert Review of Proteomics.  14:645-647.

Chapter

Year Title Altmetric
2016 Heterogeneity of aberrant O-glycosylation of IgA1 in IgA nephropathy.  53-68. 2016
2015 IgA Nephropathy and Related Diseases.  2023-2038. 2015
2009 IgA immune-complex.  177-191. 2009

Principal Investigator On

  • Molecular Basis of Pathogenicity of IgA1-Containing Immune Complexes  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2019 - 2024
  • Private Grant  awarded by RETROPHIN, INC. 2018 - 2022
  • Genetics of IgA Nephropathy by Integrative Network-Based Association Studies  awarded by Columbia University 2015 - 2021
  • Private Grant  awarded by ALEXION PHARMACEUTICALS, INC. 2018 - 2020
  • Elucidating IgA Nephropathy Through Genetic Studies of IgA1 Glycosylation  awarded by Columbia University 2014 - 2020
  • Molecular Basis of Pathogenicity of IgA1-containing Immune Complexes  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2012 - 2019
  • Aptamers-Based Arrays for Detection of Pathogenic IgA 1 O-Glycoforms in IgA Nephropathy  awarded by Columbia University 2016 - 2018
  • IgA Nephropathy and the Role of Clustered Glycosylation Initiation by GaINAc-Transferases  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2016 - 2018
  • Private Grant  awarded by ANTHERA PHARMACEUTICALS, INC 2015 - 2016
  • Private Grant  awarded by Pfizer Pharmaceuticals 2013 - 2015
  • Elucidating IgA Nephropathy Through Genetic Studies of IgA1 Glycosylation  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2009 - 2014
  • New Animal Model for Studies of Mucosal Immunity and IgA Nephropathy  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2010 - 2013
  • Urinary Polypeptide Biomakers for IgA Nephropathy  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2009 - 2012
  • Molecular Basis of Pathogenicity of 1gA1-Containing Immune Complexes  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2007 - 2012
  • IgA1-Secreting B Cell Lines: A Novel Tool for Studies of IgA Nephropathy  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2008 - 2011
  • Investigator On

  • Pathogenic Autoantibodies with Specificity for Aberrant Glycoproteins: Assessment of a Therapeutic Target in an Autoimmune Disease  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS 2020 - 2025
  • Interdisciplinary Training In Kidney-Related Research  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2019 - 2024
  • PRedoctoral Interdisciplinary Training in Renal Physiology and MEdIcIne (PRIME)  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2018 - 2023
  • Analytical Tools for the Analysis of Clustered O-Glycans in Clinical Samples  awarded by National Institute of General Medical Sciences/NIH/DHHS 2016 - 2022
  • Abnormal STAT3 Signaling and Aberrant O-Glycosylation of IgA1 in IgA Nephropathy  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2015 - 2021
  • Streptococcus Pneumoniae Capsule Inhibitor  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS 2018 - 2020
  • GDCN Clinical Center - Advancing Clinical Research in Primary Glomerular Diseases  awarded by University of North Carolina at Chapel Hill 2014 - 2019
  • UAB Center for AIDS Research  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS 2014 - 2019
  • IgA Nephropathy: Interventions with Generation of Nephritogenic Immune Complexes  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2014 - 2018
  • Analytical Tools for the Analysis of Clustered O-Glycans in Clinical Samples  awarded by National Institute of General Medical Sciences/NIH/DHHS 2011 - 2016
  • Education And Training

  • Doctor of Philosophy Level Degree in Cell / Cellular and Molecular Biology, 1990
  • Master of Sciences or Mathematics in Physiology, Pathology and Related Sciences, Charles University in Prague 1987
  • Bachelor of Science or Mathematics in Biology, Charles University in Prague 1985
  • Full Name

  • Jan Novak